Cooley advised the underwriters on Ascendis Pharma’s offering of $575 million aggregate principal amount of 2.25% Convertible Senior Notes due 2028. J.P. Morgan, Evercore ISI, Wells Fargo Securities, Morgan Stanley and Credit Suisse acted as joint book-running managers for the offering. Ascendis Pharma is a biopharmaceutical company. Partners Denny Won, Mischi a Marcha, Jason Savich, Charlie Kim, and Div Gupta led the Cooley team advising the underwriters.